|
Oct 2
|
Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
|
|
Aug 27
|
Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024
|
|
Aug 26
|
RVPH: August OLE Update
|
|
May 15
|
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
|
|
May 14
|
Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
|
May 13
|
Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference
|
|
May 9
|
Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting
|
|
Apr 25
|
RVPH: Full Year 2023 Results
|
|
Apr 15
|
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
|
|
Apr 15
|
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
|
|
Apr 15
|
RVPH: Update to Brilaroxazine Safety vs. Efficacy Comparison – Adding RECOVER Data
|
|
Mar 28
|
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting
|
|
Mar 26
|
Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting
|
|
Mar 11
|
Reviva to Present at the UBS Virtual CNS Day
|
|
Mar 7
|
Reviva to Present at the 36th Annual ROTH Conference
|
|
Feb 20
|
Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
|
|
Jan 10
|
Reviva to Present at Webull LIVE! Healthcare Webinar on January 17
|
|
Dec 26
|
Karuna downgraded, Arm target raised: Wall Street's top analyst calls
|
|
Dec 15
|
Life Science Investor Forum: Presentations Now Available for Online Viewing
|
|
Dec 12
|
Life Science Investor Forum Agenda Announced for December 14th, 2023
|